~~<i id='2E98A50BE7'><strike id='2E98A50BE7'><tt id='2E98A50BE7'><pre id='2E98A50BE7'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：fashion 2025-10-01 11:54:01 Page View：523

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ACIP vaccine advisory panel sees its vacancies filled
Next article： Duchenne breakthrough therapy leaves behind pioneering families

leisure time

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Readout LOUD podcast: Live from the 2023 STAT Summit

STATWhatifCRISPRisn’tallthatcommercial?HowdoestheNurOwnstoryend?Andhowdoyoupronounce“Bayer”?Wecovera

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

UnitedHealth, Optum discontinue NaviHealth name

MarkLennihan/APUnitedHealthGroupandOptumaregettingridofthenameoftheirtech-drivencaremanagementcompan